Impact of WTO on the Indian pharmaceutical industry

Tannan, S. K.; Tannan, Prerna
April 2004
Chemical Business;Apr/Jun2004, Vol. 18 Issue 2, p56
Trade Publication
Discusses the impact of the amendments in the Indian Patent Act done to meet their obligations to the World Trade Organization on the pharmaceutical industry. Provisions under the Indian Patent Act 1970; Details of the Doha Declaration and its implementation addressing public health problems of developing countries; Benefits of the patent law to consumers and the country's economy.


Related Articles

  • Patent policy and public health in developing countries: lessons from Japan. Aoki, Reiko; Kubo, Kensuke; Yamane, Hiroko // Bulletin of the World Health Organization;May2006, Vol. 84 Issue 5, p417 

    The article discusses on the implications of the World Trade Organization's Trade-Related Aspects of Intellectual Property Rights Agreement on the public health sector in developing countries. Under the product patent law, local pharmaceutical companies are restricted to copy manufactured drugs...

  • WHO criticised for ignoring drug dumping. Wise, Jacqui // BMJ: British Medical Journal (International Edition);09/13/97, Vol. 315 Issue 7109, p626 

    Reports on accusations against the World Health Organization (WHO) for ignoring the problem of standard drugs being dumped in developing countries. WHO's failure to lead the prevention of unacceptable trading practices in supply lines; Consequences of drug dumping; Changes on WHO's work...

  • Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health? Oliveira, Maria Auxiliadora; Bermudez, Jorge Antonio Zepeda; Chaves, Gabriela Costa; Velásquez, Germán // Bulletin of the World Health Organization;Nov2004, Vol. 82 Issue 11, p815 

    Objective The World Trade Organization's Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement establishes minimum standards for intellectual property rights, including patent protection for pharmaceuticals; therefore, it may make it difficult for developing countries to gain...

  • Vantage Point. Vanderveer, Richard B. // Medical Marketing & Media;Feb2008, Vol. 43 Issue 2, p32 

    The author reflects on the report by Oxfam International entitled "Investing for Life—Meeting Poor People's Needs for Access to Medicines through Responsible Business Practices." According to him, the report talks about one of the key responsibilities of pharmaceutical companies which is...

  • U.N. Study: Quota End Will Hurt Poor Nations. Zarocostas, John // WWD: Women's Wear Daily;10/4/2004, Vol. 188 Issue 71, p23 

    Presents information on a study conducted by the United Nations Conference of Trade & Development in 2004 regarding the economic effect of quota elimination on least developed countries. Number of member countries of the World Trade Organization; Least-developed countries that will be affected...

  • Counterfeit and substandard quality of drugs: The need for an effective and stringent regulatory control in India and other developing countries. Khan, Azhar Yaqoob; Ghilzai, Naushad M. Khan // Indian Journal of Pharmacology;Aug2007, Vol. 39 Issue 4, p206 

    The article discusses the implications of counterfeit and substandard quality of drugs on an effective and stringent regulatory control in India and other developing countries. The World Health Organization (WHO) defined counterfeit drug as one which is deliberately and fraudulently mislabeled...

  • ACCESS TO MEDICINES. Reinhardt, Erika // UN Chronicle;Sep-Nov2006, Vol. 43 Issue 3, p56 

    The article provides information on the developing countries where it is estimated that one third of the population is unable to receive or purchase essential medicines on a regular basis. Most trade in medicines takes place between wealthy countries, with the developing nations accounting for...

  • China Joins Global Health Governance: New Player, More Medicines, and New Rules? Lee, Pak K.; Lai-Ha Chan // Global Governance;Apr-Jun2014, Vol. 20 Issue 2, p297 

    In the wake of China's rapid ascendancy, are there any new rules made by the country in global health governance? This article examines China's emerging role in the Agreement on Trade Related Aspects of Intellectual Property Rights and finds that China adopts a pro-status quo stance on patented...

  • "No turning back" on cheap AIDS drugs for poor nations, UN vows. Silversides, Ann // CMAJ: Canadian Medical Association Journal;11/11/2003, Vol. 169 Issue 10, p1067 

    Emphasizes the need to modify the Patent Act in Ottawa, Ontario, to allow Canadian manufacturers of generic drugs to make and export drugs to developing countries. Implications of the proposed drug exportation for Canadian pharmaceutical companies; Impact of the decision of the World Trade...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics